#TALENT at #ESMO26 🇪🇸 : neoadjuvant T-DXd alone, T-DXd + anastrozole, or T-DXd followed by TC showed high response rates but pCR <10% across all arms in HR+/HER2-low early #Brea

Kristina Jankovic, MD· @JankovicK · X·2026-10-24 02:22· 1 天前评分70

正文 · 原文

#TALENT at #ESMO26 🇪🇸 : neoadjuvant T-DXd alone, T-DXd + anastrozole, or T-DXd followed by TC showed high response rates but pCR <10% across all arms in HR+/HER2-low early #BreastCancer

Better biomarkers are needed to guide patient selection.

@OncoAlert

264 浏览 · 4 赞 · 4 转发 · 1 回复

会议摘要

LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上

Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer

https://esmocongress.esmo.org

帖内回复

Dr. Robert@robt_heartdoc
@JankovicK @OncoAlert The quiet finding in this figure: histology and IHC status didn't track with response at all. If nothing correlates, we're treating empirically and calling it precision oncology. My interest now is the EFS data.

来源：Kristina Jankovic, MD · x.com